Abstract #0525
TMPRSS2:ERG gene fusion and ERG overexpression in human prostate cancer are associated with changed metabolism
Ailin Falkmo Hansen 1 , Elise Sandsmark 1 , Morten Beck Rye 2,3 , Alan Wright 4 , Helena Bertilsson 2,5 , Anna M. Bofin 6 , Anders Angelsen 1 , Tone Frost Bathen 1 , and May-Britt Tessem 1,3
1
Department of Circulation and Medical
Imaging, Norwegian University of Science and Technology
(NTNU), Trondheim, Norway,
2
Department
of Cancer Research and Molecular Medicine, Norwegian
University of Science and Technology (NTNU), Trondheim,
Norway,
3
St.
Olavs Hospital, Trondheim, Norway,
4
Cancer
Research UK Cambridge Institute, University of
Cambridge, Cambridge, United Kingdom,
5
Department
of Urology, St. Olavs Hospital, Trondheim, Norway,
6
Department
of Laboratory Medicine, Children's and Women's Health,
Norwegian University of Science and Technology (NTNU),
Trondheim, Norway
TMPRSS2-driven overexpression of ERG has been shown to
be associated with several markers for prostate cancer
aggressiveness, although its clinical significance is
not fully understood. The aim of this study was to
investigate metabolic alterations associated with ERG
overexpression/TMPRSS2:ERG to increase the biological
understanding of TMPRSS2:ERG fusion in prostate cancer
patients. Prostate tissue samples (n=95) and prostate
biopsy samples (n=40) were analyzed by 1H HR-MAS MRS. In
ERG-high samples, citrate and spermine were
significantly decreased compared to ERG-low samples.
These results were validated in biopsy samples by
FISH-detected TMPRSS2:ERG and suggest altered citrate
and spermine metabolism due to ERG
overexpression/TMPRSS2:ERG.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
